Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2015-07-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2015年第三次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and results of a specific shareholders' meeting (the 2015 third extraordinary general meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the legality of the meeting notice, attendance, voting procedures, and resolutions passed. It is not the meeting materials themselves, nor the voting results announcement in a formal sense, but a legal opinion on the meeting's compliance with laws and company rules. The document is short (1390 characters) and focuses on legal compliance rather than financial data or management discussion. This fits best under Regulatory Filings (RNS) as a legal opinion related to a shareholder meeting, not an AGM Information presentation or Declaration of Voting Results. Therefore, the classification is RNS with high confidence.
2015-07-24 Chinese
2015年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at an extraordinary shareholders meeting held on July 24, 2015. It includes voting results on various proposals such as acquisition of shares, resignation and appointment of directors and supervisors, attendance details, and legal witness statements. The content focuses on the outcomes of shareholder votes and changes in board composition rather than financial results or management discussion. The document length is under 5,000 characters and it is not a report itself but a formal announcement of voting results from a shareholders meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2015-07-24 Chinese
北京德恒（昆明）律师事务所关于公司2013年授予股权激励所涉限制性股票第二次解锁事宜的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the unlocking of restricted shares related to a 2013 equity incentive plan of Kunming Pharmaceutical Group Co., Ltd. It discusses legal compliance, conditions for unlocking restricted stock, and procedural approvals. It is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to a corporate equity incentive event. This type of document does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a specialized legal opinion related to share unlocking under an equity incentive plan, which is best classified under Regulatory Filings (RNS) as it does not match any other specific category and is a compliance/legal document.
2015-07-21 Chinese
七届二十一次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by Kunming Pharmaceutical Group Co., Ltd. It includes details about the meeting date, participants, and the resolution passed regarding the unlocking of stock options from 2013. The document is short (541 characters) and does not contain financial statements or detailed financial data. It is not a full report but an official announcement of a board/management decision. Therefore, it fits best under Board/Management Information (MANG).
2015-07-21 Chinese
北京德恒（昆明）律师事务所关于公司2013年授予股权激励所涉限制性股票第二次解锁事宜的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the unlocking of restricted shares related to a 2013 equity incentive plan of Kunming Pharmaceutical Group Co., Ltd. It discusses legal compliance, conditions for unlocking restricted stock, and procedural approvals. It is not a financial report, earnings release, or regulatory filing about financial results. It is a standalone legal opinion related to a specific corporate action (equity incentive unlocking). This fits best under the category of Legal Proceedings Report (LTR), as it involves legal opinions on corporate governance and compliance matters related to stock incentives.
2015-07-21 Chinese
关于2013年授予股权激励股票第二次解锁的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the second unlocking of restricted stock granted under the 2013 equity incentive plan. It details the number of shares unlocked, the unlocking date, the conditions for unlocking, and legal opinions confirming compliance with regulations. The document is a formal disclosure about the unlocking event of equity incentive shares, which is a capital change event related to share issuance and transfer restrictions being lifted. It is not a full financial report, earnings release, or management discussion, nor is it a proxy or voting result announcement. The document length is 4281 characters, which is relatively short but contains detailed information about share unlocking. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2015-07-21 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.